Incyte | INCY - 营业费用



金融业
股票价格
USD
资产
USD 7.87B
现金及等价物
USD 3.98B
销售成本
USD 104.96M
流动资产
USD 6.03B
流动负债
USD 1.31B
债务
USD 38.27M
EBIT
USD 700.4M
EBITDA
USD 778.57M
员工
2.62K
EPS每股收益
USD 3.09
股本和储备
USD 6.34B
销售毛利
USD 1.57B
债务利息支出
USD 582K
利息收入
USD 38.12M
贷款资金
USD 28.42M
市值
USD 25.72B
净收入
USD 585.61M
营业费用
USD 973.64M
营业利润
USD 700.4M
普通股股本
USD 200.98M
PE价格收益
14.45
税前利润
USD 751.51M
销售收入
USD 1.67B
销售和管理费用
USD 351.74M
股票
USD 112.54M
贸易债权人
USD 1.39B
应收帐款人
USD 1.13B


营业费用 更改 日
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agenus USD -199.08M 22.15M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amgen USD 11.69B 6.9B 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Biogen USD 2.98B 1.02B 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Exelixis USD 380.28M 20.8M 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 15.77B 2.4B 2026-06
Moderna USD 960M 817M 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novartis USD 10.2B 912M 2026-06
Novartis USD 9.29B 507M 2026-03
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06